Iranian Society of Gynecology Oncology

Document Type : Original Research Article


1 Department of Obstetrics and Gynecology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 Department of Obstetrics and Gynecology, School of Medicine, Imam Hossein hospital, Iran University of Medical Sciences, Tehran, Iran

3 Department of Biology, Science and Research Unit, University of Tehran, Tehran, Iran


Background & Objective: Gynecological cancer survivors have been growing, as a result of advancements in national cancer screening strategies, resulting in early-stage diagnosis, and cancer treatments developments. Lack of a valid documented assessment tool to measure their requirements for supportive care is detected. The aim was to develop a comprehensive scale that comprises all features of gynecologic cancer survivors` requirements in Iranian population.
Materials & Methods: The Cancer Survivors Assessment Questionnaire NCCN2.2020 (National comprehensive cancer network) was translated including the instructions, and the answer choices by two native translators, including one fluent translator and one linguist. For qualitative face validity of the questionnaire at the disposal of 10 specialists were delegated to make the necessary changes. Content validity and content validity index were evaluated in terms of qualitative face validity and quantitative face validity. Necessary changes were applied.
Results: The original Cancer Survivors Assessment Questionnaire NCCN2.2020 (National comprehensive cancer network) was condensed from 27 to 24 questions during the customization process. Questions related to lymphedema, and immunization were eliminated from the survey, as a result of low content validity index and scores. According to the panel of experts, ten questions including number 3, 5, 6, 9, 10, 13, 17, 18, 19, and 25 of the questionnaires were changed to a more suitable and comprehensible ones in Persian language.
Conclusion: We suggest that the Persian version of cancer survivors’ assessment questionnaire be applied in populations with Persian language and that its sensitivity to variation be measured.


 We suggest that the Persian version of cancer survivors’ assessment questionnaire be applied in populations with Persian language and that its sensitivity to variation be measured.


Main Subjects

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: Cancer J Clin. 2018;68(1):7-30. [DOI:10.3322/caac.21442] [PMID]
2. Riba MB, Donovan KA, Andersen B, Braun I, Breitbart WS, Brewer BW, et al. Distress management, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2019;17(10):1229-49. [DOI:10.6004/jnccn.2019.0048] [PMID] [PMCID]
3. Grover S, Hill-Kayser CE, Vachani C, Hampshire MK, DiLullo GA, Metz JM. Patient reported late effects of gynecological cancer treatment. Gynecol Oncol. 2012;124(3):399-403. [DOI:10.1016/j.ygyno.2011.11.034] [PMID]
4. Hewitt M, Greenfield S, Stovall E. From cancer patient to cancer survivor: lost in transition: National Academies Press; 2005.
5. Nekhlyudov L, Ganz PA, Arora NK, Rowland JH. Going Beyond Being Lost in Transition: A Decade of Progress in Cancer Survivorship. J Clin Oncol. 2017;35(18):1978-81. [DOI:10.1200/JCO.2016.72.1373] [PMID] [PMCID]
6. Chan R, Nekhlyudov L. Overview of cancer survivorship care for primary care and oncology providers. 2021.
7. Denlinger CS, Sanft T, Moslehi JJ, Overholser L, Armenian S, Baker KS, et al. NCCN guidelines insights: survivorship, version 2.2020: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2020;18(8):1016-23. [DOI:10.6004/jnccn.2020.0037] [PMID] [PMCID]
8. Truant TL, Fitch MI, O'Leary C, Stewart J. Global perspectives on cancer survivorship: From lost in transition to leading into the future. Can Oncol Nurs J. 2017;27(3):287-94.
9. Razmi N, Hasanzadeh M. Current advancement on diagnosis of ovarian cancer using biosensing of CA 125 biomarker: Analytical approaches. Trends Analyt Chem. 2018;108:1-12. [DOI:10.1016/j.trac.2018.08.017]
10. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191-e203. [DOI:10.1016/S2214-109X(19)30482-6] [PMID]
11. Cardoso F, van 't Veer L, Poncet C, Lopes Cardozo J, Delaloge S, Pierga J-Y, et al. MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients. J Clin Oncol. 2020;38(15_suppl):506. [DOI:10.1200/JCO.2020.38.15_suppl.506]
12. Wijayabahu AT, Egan KM, Yaghjyan L. Uterine cancer in breast cancer survivors: a systematic review. Breast Cancer Res Treat. 2020;180(1):1-19. [DOI:10.1007/s10549-019-05516-1] [PMID]
13. Filippova OT, Leitao MM. The current clinical approach to newly diagnosed uterine cancer. Expert Rev Anticancer Ther. 2020;20(7):581-90. [DOI:10.1080/14737140.2020.1782750] [PMID] [PMCID]
14. Lewin SN, Wright JD. Comparative Performance of the 2009 International Federation of Gynecology and Obstetrics' Staging System for Uterine Corpus Cancer. Obstet Gynecol. 2011;117(5). [DOI:10.1097/AOG.0b013e3182167973] [PMID]
15. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95 Suppl 1:S105-43. [DOI:10.1016/S0020-7292(06)60031-3]
16. Rahmani A, Ferguson C, Jabarzadeh F, Mohammadpoorasl A, Moradi N, Pakpour V. Supportive care needs of Iranian cancer patients. Indian J Palliat Care. 2014;20(3):224-8. [DOI:10.4103/0973-1075.138400] [PMID] [PMCID]
17. Marcoux V, Chouinard M-C, Diadiou F, Dufour I, Hudon C. Screening tools to identify patients with complex health needs at risk of high use of health care services: a scoping review. PLoS One. 2017;12(11):e0188663. [DOI:10.1371/journal.pone.0188663] [PMID] [PMCID]
18. Syse A, Geller B. A Cross-Cultural Perspective on Challenges Facing Comparative Cancer Survivorship Research. J Cancer Epidemiol. 2011;2011:689025. [DOI:10.1155/2011/689025] [PMID] [PMCID]
19. Guidry JJ, Torrence W, Herbelin S. Closing the divide: Diverse populations and cancer survivorship. Cancer. 2005;104(S11):2577-83. [DOI:10.1002/cncr.21251] [PMID]
20. Haryani H, Afiyanti Y, Besral B, Gayatri D, Wahidi KR, Pramiasti H, et al. Cross-cultural adaptation and validation of the cancer survivors' unmet needs measure among gynecological cancer patients in Indonesia. Arch Oncol. 2020;26(2):23-9. [DOI:10.2298/AOO190531011H]
21. Hambleton RK, Kanjee A. Increasing the validity of cross-cultural assessments: Use of improved methods for test adaptations. Eur J Psychol Assess. 1995;11(3):147-57. [DOI:10.1027/1015-5759.11.3.147]
22. Hilton A, Skrutkowski M. Translating Instruments Into Other Languages: Development and Testing Processes. Cancer Nurs. 2002;25(1). [DOI:10.1097/00002820-200202000-00001] [PMID]
23. Geisinger KF. Cross-cultural normative assessment: Translation and adaptation issues influencing the normative interpretation of assessment instruments. Psychol Assess. 1994;6(4):304. [DOI:10.1037/1040-3590.6.4.304]
24. Nicholson NS. Translation and Interpretation. Annu Rev Linguist. 1995;15:42 - 62. [DOI:10.1017/S0267190500002609]